Telomerase activity in stage II colorectal carcinoma: Telomerase-negative tumors are correlated with poor prognosis

Cancer

Volumn 95, Issue 9, 2002, Pages 1834-1839

  Kawanishi Tabata, Rika ^a   Lopez, Francisco ^b   Fratantonio, Sam ^b   Kim, Nam ^c   Goldblum, John ^b   Tubbs, Raymond ^b   Elson, Paul ^a   Lavery, Ian ^b   Bukowski, Ronald M ^a   Ganapathi, Ram ^a   Ganapathi, Mahrukh K ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c diaDexus Inc   (United States)

Author keywords

Colorectal carcinoma; Disease free survival; Prognosis; Telomerase activity

Indexed keywords

TELOMERASE;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR CLASSIFICATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE; TELOMERASE;

EID: 0036839703     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10911     Document Type: Article

References (30)

1. Blackburn EH. Structure function of telomeres. Nature. 1991;350:569-573.
2. Zakain VA. Telomeres, beginning to understand the end. Science. 1995;270:1601-1607.
3. Greider CW. Telomere length regulation. Annu Rev Biochem. 1996;65:337-365.
4. McEachern MJ, Krauskopf A, Blackburn EH. Telomere and their control. Annu Rev Genet. 2000;34:331-358.
5. Greider CW. Telomeres and senescence: The history, the experiment, the future. Curr Biol. 1998;81:178-181.
6. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921-1929.
7. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43:405-413.
8. Greider CW, Blackburn EH. A telomeric sequence in the the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature. 1989;337:331-337.
9. Smith SA, deLange T. TRF1, a mammalian telomeric protein. Trends Genet 1997;13:21-26.
10. Kim NM, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
11. Shay JW, Bacchetti S. A survey of telomerase activit in human cancer. Eur J Cancer. 1997;33:787-791.
12. Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer. 1997;33:781-786.
13. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med. 1995;1:249-255.
14. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am. 1996;274:92-97.
15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
16. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bachetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 1994;55:2533-2536.
17. Tang R, Cheng AJ, Wang JY, Wang TC. Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res. 1998;58:4052-4054.
18. Okayasu I, Mitomi H, Yamashita K, et al. Telomerase activity significantly correlates with cell differentiation, proliferation and lymph node metastasis in colorectal carcinomas. J Cancer Res Clin Oncol. 1998;124:444-449.
19. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997;89:1874-1880.
20. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4918-4922.
21. Marchetti A, Bertacca G, Buttitta F, et al. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res. 1999;5:2077-2081.
22. Takagi S, Kinouchi Y, Hiwatashi N, et al. Telomere shortening and the clinicopathological characteristics of human colorectal carcinomas. Cancer. 1999;861431-1436.
23. Pardue ML, DeBaryshe PG. Telomeres and telomerase: More than the end of the line. Chromosoma. 1999;108:73-82.
24. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240-4248.
25. Bitisik O, Yavuz S, Yasasever V, Dalay N. Telomerase activity in patients with chronic myeloid leukemia and lymphoma. Res Commun Mol Pathol Pharmacol. 2000;107:3-12.
26. Greenberg R, Chin L, Femino A, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a (delta 2/3) cancer-prone mouse. Cell. 1999;97:515-525.
27. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 1999;97:527-538.
28. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717-7722.
29. Rizki A, Lundblad V. Defects in mismatch repair promote telomerase-independent proliferation. Nature. 2001;411:713-716.
30. Kucherlapati R, DePinho RA. Telomerase meets its mismatch. Nature. 2001;411:647-648.